Drug Trial Radar · NCT02023697
Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone
Last checked: Nov 20, 2026Latest source record: Jul 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
391
Actual
Start
Mar 10, 2014
Primary completion
Mar 1, 2017
Study completion Aug 9, 2018
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Dec 30, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess different doses and regimens of radium-223 dichloride on the incidence of symptomatic skeletal events. Eligible subjects must have castration resistant prostate cancer with 2 or more skeletal metastases documented within 8 weeks of randomization. Subjects will be randomized to one of 3 treatment arms in a 1:1:1 fashion: a standard regimen of radium-223 dichloride of 50 kBq/kg (55 kBq/kg after implementation of NIST update) injections every month for 6 months, a high dose regimen of 80 kBq/kg (88 kBq/kg after implementation of NIST update)injections every month for 6 months or an extended duration regimen of 50 kBq/kg (55 kBq/kg after implementation of NIST update) injections every month for 12 months. Following the treatment phase, subjects will be followed up every 12 weeks for a minimum of 2 years, at which point they will enter a long term follow-up period during which they are seen every 6 months for up to 7 years after the last dose of radium dichloride. Symptomatic skeletal event and safety endpoints will be assessed at each clinic visit. Pain and analgesic use data will be collected every 4 weeks through Week 48. Additionally, radiological assessments including MRI/CT of the abdomen and pelvis and chest CT, as well as technetium-99 bone scans will be performed at Weeks 8, 16, and 24 and continue every 12 weeks thereafter until disease progression is documented in either the bone or in soft tissue. Radiological imaging will be evaluated by blinded central review.
Conditions
- Prostatic Neoplasms
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With an Event Defining SSE Free Survival - High Dose vs. Standard DoseTime frame: From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
- Symptomatic Skeletal Event-Free Survival - High Dose vs. Standard DoseTime frame: From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
- Number of Participants With an Event Defining SSE Free Survival - Extended Dose vs. Standard DoseTime frame: From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
- Symptomatic Skeletal Event-Free Survival - Extended Dose vs. Standard DoseTime frame: From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
- Number of Participants With an Event Defining SSE Free Survival - Three Dose Groups As RandomizedTime frame: From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
- Symptomatic Skeletal Event Free Survival - Three Dose Groups As RandomizedTime frame: From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Locations
68 sites in 15 countries. Site status is shown where the registry gives one.
Site not named
Scottsdale, Arizona
Site not named
New Haven, Connecticut
Site not named
Fort Myers, Florida
Site not named
Bethesda, Maryland
Site not named
Rockville, Maryland
Site not named
Ann Arbor, Michigan
Site not named
Detroit, Michigan
Site not named
St Louis, Missouri
Site not named
Omaha, Nebraska
Site not named
East Setauket, New York
Site not named
Portland, Oregon
Site not named
Pittsburgh, Pennsylvania
Site not named
Box Hill, Australia
Site not named
Darlinghurst, Australia
Site not named
Westmead, Australia
Site not named
Adelaide, South Australia, Australia
Site not named
Melbourne, Victoria, Australia
Irmandade Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Instituto do Câncer do Estado de São Paulo
São Paulo, São Paulo, Brazil
IBCC - Instituto Brasileiro de Controle do Cancer
São Paulo, São Paulo, Brazil
Hospital Israelita Albert Einstein
São Paulo, São Paulo, Brazil
Site not named
London, Ontario, Canada
Site not named
Ottawa, Ontario, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Montreal, Quebec, Canada
Site not named
Santiago, Chile
Site not named
Chomutov, Czechia
Site not named
Prague, Czechia
Site not named
Nantes, France
Site not named
Vandœuvre-lès-Nancy, France
Site not named
Villejuif, France
Site not named
Tübingen, Baden-Wurttemberg, Germany
Site not named
München, Bavaria, Germany
Site not named
Dresden, Saxony, Germany
Site not named
Beersheba, Israel
Site not named
Haifa, Israel
Site not named
Jerusalem, Israel
Site not named
Kfar Saba, Israel
Showing 40 of 68 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.